Key Takeaways:
GeneDx Holdings Corp. investors have until Aug. 3 to seek lead plaintiff status in a securities class action alleging the genomic testing company concealed deteriorating reimbursement rates and margin compression, according to Levi & Korsinsky LLP.
"The lawsuit asserts that throughout the Class Period, management made statements that painted a misleading picture of GeneDx's reimbursement trajectory," Joseph E. Levi, Esq. at Levi & Korsinsky, said in a statement.
The blended average reimbursement rate per test fell from more than $3,800 in the third quarter of 2025 to about $3,750 in the fourth quarter, then collapsed to $3,300 in the first quarter of 2026 — a decline of more than $500 per test in two quarters. Adjusted gross margin contracted five percentage points to 69% in the first quarter from a peak of 74% in the third quarter of 2025. The company slashed its full-year 2026 revenue guidance by about $65 million at the midpoint, to a range of $475 million to $490 million from $540 million to $555 million.
The complaint also alleges GeneDx misled investors about its acquisition of Fabric Genomics, an AI-driven genomic interpretation company valued at up to $51 million. On May 4, 2026, the company disclosed a $31.2 million impairment loss tied to Fabric, missed revenue estimates for both its exome and genome testing lines, and cut guidance. Shares fell $33.42, or 49.2%, on the news. The class period runs from April 16, 2025 through May 4, 2026.
A separate complaint filed by Robbins LLP alleges GeneDx failed to disclose material problems with Fabric's viability before the acquisition closed. The company had represented that Fabric's interpretation-as-a-service model would create recurring software-based revenue and generate efficiencies with GeneDx's existing business. The lawsuits seek damages on behalf of investors who purchased WGS common stock during the class period.
The lead plaintiff deadline of Aug. 3 applies to both actions. Securities class actions typically take two to four years from initial filing to resolution, according to Levi & Korsinsky. The decline puts GeneDx shares at their lowest level since the disclosure, testing investor confidence in the company's core reimbursement trajectory. Investors will watch for any further guidance updates or payer contract disclosures in the coming quarters.
This article is for informational purposes only and does not constitute investment advice.
